Cancer
Neoplasm of Uncertain Histogenesis
CI-CAN-00000034Explore in graph →
Non-malignant20,280 active trials259 approved drugs3,813 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00000034Explore in graph →
Clinical trials
91,351 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07390539 | B7-H3.CD28Z.CART in CNS Neoplasms | recruiting | Phase 1 | 70 | Robbie MajznerOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT07491497 | A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC | recruiting | Phase 1 / Phase 2 | 160 | TRIANA Biomedicines, Inc.INDUSTRY | 2 | Sep 3, 2026 | clinicaltrials |
| NCT07539441 |
| recruiting |
| Phase 1 / Phase 2 |
| 26 |
| Memorial Sloan Kettering Cancer CenterOTHER |
| 1 |
| Sep 3, 2026 |
| clinicaltrials |
| NCT07545811 | Study of JANX014 in Subjects With Metastatic Castration-Resistant Prostate Cancer | recruiting | Phase 1 | 43 | Janux TherapeuticsINDUSTRY | 1 | Sep 3, 2026 | clinicaltrials |
| NCT07602842 | A Study of IDP-001 in Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 132 | InduPro, Inc.INDUSTRY | 1 | Sep 3, 2026 | clinicaltrials |
| NCT07725380 | Domatinostat With Sirolimus for Relapsed, Refractory Sarcoma and Osteosarcoma | recruiting | Phase 1 / Phase 2 | 74 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT07755436 | Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of ARR-002 in Advanced or Metastatic Ovarian or Endometrial Cancer. | recruiting | Phase 1 | 180 | ArriVent BioPharma, Inc.INDUSTRY | 1 | Sep 3, 2026 | clinicaltrials |
| NCT04913285 | A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors | recruiting | Phase 1 | 400 | Pierre Fabre MedicamentINDUSTRY | 7 | Sep 2, 2026 | clinicaltrials |
| NCT05245500 | Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion | recruiting | Phase 1 | 336 | Bristol-Myers SquibbINDUSTRY | 1 | Sep 2, 2026 | clinicaltrials |
| NCT05319730 | A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B) | recruiting | Phase 1 / Phase 2 | 230 | Merck Sharp & Dohme LLCINDUSTRY | 14 | Sep 2, 2026 | clinicaltrials |
| NCT05918640 | Lurbinectedin in FET-Fused Tumors(LiFFT) | recruiting | Phase 1 / Phase 2 | 63 | Children's Hospital of PhiladelphiaOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT06043817 | First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations | recruiting | Phase 1 / Phase 2 | 345 | Pierre Fabre MedicamentINDUSTRY | 7 | Sep 2, 2026 | clinicaltrials |
| NCT06251310 | SW-682 in Advanced Solid Tumors | recruiting | Phase 1 | 186 | SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, GermanyINDUSTRY | 1 | Sep 2, 2026 | clinicaltrials |
| NCT06469944 | Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06) | recruiting | Phase 1 / Phase 2 | 160 | Merck Sharp & Dohme LLCINDUSTRY | 12 | Sep 2, 2026 | clinicaltrials |
| NCT06488378 | Phase Ib Study of Axatilimab in Combination With Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast Cancer | recruiting | Phase 1 | 20 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT06567015 | Study of FIH of STX-241 in Locally Advanced or Metastatic NSCLC Resistant to EGFR TKIs(STX-241 FIH) | recruiting | Phase 1 / Phase 2 | 171 | Pierre Fabre MedicamentINDUSTRY | 7 | Sep 2, 2026 | clinicaltrials |
| NCT06673017 | PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC) | recruiting | Phase 1 | 26 | PanTher TherapeuticsINDUSTRY | 2 | Sep 2, 2026 | clinicaltrials |
| NCT06860594 | Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma | recruiting | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07024615 | A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer | recruiting | Phase 1 | 25 | Astellas Pharma Global Development, Inc.INDUSTRY | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07027514 | A Study of Tolododekin Alfa (ANK-101) in Combination With an Anti-PD-1/PD-L1 Antibody in Participants With Advanced Non-Small Cell Lung Cancer | recruiting | Phase 1 | 60 | Ankyra Therapeutics, IncINDUSTRY | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07192614 | A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer(ACTIVATED-4-PC) | recruiting | Phase 1 / Phase 2 | 52 | AstraZenecaINDUSTRY | 9 | Sep 2, 2026 | clinicaltrials |
| NCT07216105 | FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 119 | Fate TherapeuticsINDUSTRY | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07347418 | CD64 CAR T Cell Therapy in Adults With Relapsed and/or Refractory AML | recruiting | Phase 1 | 23 | University of Colorado, DenverOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07625423 | Intratumoral Injection of Recombinant Human Endostatin Adenovirus (EDS01) for the Treatment of Recurrent or Metastatic Head and Neck Tumors(EDS01 HN) | recruiting | Phase 1 | 9 | West China HospitalOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07690618 | Thermotherapy for Head and Neck Cancer Patients(TANCAP-I) | recruiting | Phase 1 | 30 | Erasmus Medical CenterOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07783477 | A Study of Armored CAR T Cells in People With Cancer | recruiting | Phase 1 | 16 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT03900793 | Losartan + Sunitinib in Treatment of Osteosarcoma | recruiting | Phase 1 | 41 | University of Colorado, DenverOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT04172532 | Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer | recruiting | Phase 1 / Phase 2 | 92 | National Cancer Institute (NCI)NIH | 1 | Sep 1, 2026 | clinicaltrials |
| NCT05322850 | Phase I/II Trial: Engineered Donor Graft (Orca Q) for Pediatric Hematopoietic Cell Transplant (HCT) | recruiting | Phase 1 / Phase 2 | 40 | University of FloridaOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT05958121 | IMA402 T Cell-Engaging Receptor Molecule (TCER®) in Recurrent and/or Refractory Solid Tumors | recruiting | Phase 1 / Phase 2 | 400 | Immatics Biotechnologies GmbHINDUSTRY | 2 | Sep 1, 2026 | clinicaltrials |
| NCT06291987 | Ivosidenib and Ruxolitinib in Patients With Advanced Myeloproliferative Neoplasms (MPNs) That Have an IDH1 Gene Mutation(MPN) | recruiting | Phase 1 | 18 | University of ChicagoOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT06294548 | A Study of Valemetostat Tosylate (DS-3201b) With Atezolizumab and Bevacizumab in HCC | recruiting | Phase 1 / Phase 2 | 45 | University of Alabama at BirminghamOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT06408194 | Autologous CD22 CAR T Cells Following Commercial CD19 CAR T Cells in B Cell Malignancies | recruiting | Phase 1 | 28 | Stanford UniversityOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT07025564 | MiRisten for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia | recruiting | Phase 1 | 20 | City of Hope Medical CenterOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT07227571 | Genetically Engineered Cells (FH-FOLR1 ST CAR T Cells) for the Treatment of Advanced Refractory or Recurrent/Progressive Osteosarcoma, FIERCe Trial | recruiting | Phase 1 | 30 | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT07232602 | KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04) | recruiting | Phase 1 / Phase 2 | 55 | Merck Sharp & Dohme LLCINDUSTRY | 8 | Sep 1, 2026 | clinicaltrials |
| NCT07332507 | Testing the Effect of Teclistamab on Recurrent Plasmablastic Lymphoma | recruiting | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Sep 1, 2026 | clinicaltrials |
| NCT07432022 | A Phase I/II Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of the EMB-07 Combination Therapy in Patients With Aggressive B-Cell Non-Hodgkin Lymphoma | recruiting | Phase 1 / Phase 2 | 115 | Shanghai EpimAb Biotherapeutics Co., Ltd.INDUSTRY | 1 | Sep 1, 2026 | clinicaltrials |
| NCT07545122 | A Phase 1a/1b, First-Time-in-Human Study of CT-202, a Nectin-4 Directed Bispecific Antibody, in Participants With Recurring Triple Negative Breast, Colorectal, Urothelial Cancers(CT-202) | recruiting | Phase 1 | 162 | Context Therapeutics Inc.INDUSTRY | 1 | Sep 1, 2026 | clinicaltrials |
| NCT07586618 | First-in-human Study of a New Treatment (4A10) for Patients With Relapsed or Hard-to-treat Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma, Focused on Safety and How the Drug Behaves in the Body and Early Signs of Effect.(ALT-101) | recruiting | Phase 1 | 24 | Allterum Therapeutics, IncINDUSTRY | 1 | Sep 1, 2026 | clinicaltrials |
| NCT07736937 | Study of TUB-040 Given With Standard Ovarian Cancer Drugs in Patients With Fast-growing Ovarian Cancer(OC) | recruiting | Phase 1 / Phase 2 | 72 | Tubulis GmbHINDUSTRY | 3 | Sep 1, 2026 | clinicaltrials |
| NCT04881240 | Study of CD19 Allogeneic Memory T-cell Therapy for Relapsed/Refractory CD19+ Leukemia | recruiting | Phase 1 | 60 | St. Jude Children's Research HospitalOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT05536141 | A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors(ARC-20) | recruiting | Phase 1 | 362 | Arcus Biosciences, Inc.INDUSTRY | 4 | Aug 31, 2026 | clinicaltrials |
| NCT05896839 | Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer | recruiting | Phase 1 / Phase 2 | 16 | National Cancer Institute (NCI)NIH | 1 | Aug 31, 2026 | clinicaltrials |
| NCT05942001 | Study of HRS-5041 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) | recruiting | Phase 1 | 100 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Aug 31, 2026 | clinicaltrials |
| NCT06075810 | A Study of Oral MBQ-167 in Participants With Advanced Breast Cancer | recruiting | Phase 1 | 48 | MBQ PharmaINDUSTRY | 2 | Aug 31, 2026 | clinicaltrials |
| NCT06460298 | ProAgio in Combination With Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer | recruiting | Phase 1 / Phase 2 | 51 | ProDa BioTech, LLCINDUSTRY | 1 | Aug 31, 2026 | clinicaltrials |
| NCT06461156 | A Study of HS-10504 in Patients With Advanced or Metastatic Non-Small-Cell Lung Cancer(NSCLC) | recruiting | Phase 1 | 230 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 31, 2026 | clinicaltrials |
| NCT06600698 | Safety and Efficacy of AGN-INM176 in Prostate Patients With Rising PSA | recruiting | Phase 1 / Phase 2 | 45 | Milton S. Hershey Medical CenterOTHER | 1 | Aug 31, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Sep 3, 2026source: clinicaltrials